Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Clin Med Res ; 16(4): 138-154, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38715555

ABSTRACT

Spinal cord injury (SCI) is a traumatic event that significantly impacts body composition and alters energy and nutritional needs. This places patients with SCI at a high risk of malnutrition, which can hinder optimal functional recovery, prolong hospital stays, increase hospital admissions, and contribute to the development of obesity and cardiovascular and metabolic ailments in chronic patients. Consequently, there is an urgent need for clear guidance to support clinicians in managing the nutritional needs of patients with SCI at different stages of the disease, including the acute (0 - 4 months after injury), post-acute (4 - 26 months after injury), and post-discharge phases. This study utilized a cross-sectional survey to assess the strategies employed in seven spinal units across Italy to address the nutritional needs of patients with SCI during the acute, post-acute, and post-discharge phases of the condition. Eight clinicians (five physiatrists, two internists, and one urologist) and one nurse participated in the survey. Following the survey completion, the participants were invited to partake in a round table session to delve deeper into the questionnaire results to gather their opinions and gain insights into clinical practices related to the various challenges surrounding the management of malnutrition in patients with SCI. We here review the available evidence on the energy needs and nutritional requirements of patients with SCI, highlighting the clinical aspects that deserve more attention throughout the distinct phases of the disease. We additionally provide an overview of the scenario regarding the management of malnutrition in patients with SCI across various spinal units in Italy. Through this comprehensive analysis, we aimed to enhance understanding and provide valuable insights for clinicians working with patients with SCI, equipping them with the knowledge and confidence to provide nutritional support to patients with SCI efficiently. By addressing the challenges of defining nutritional needs and presenting a practical guide, we aspire to contribute to the overall management and care of individuals with SCI and the prevention of malnutrition and its associated complications, thereby improving patient outcomes.

2.
J Crohns Colitis ; 5(3): 218-21, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21575884

ABSTRACT

BACKGROUND AND AIMS: The long-term natural history of collagenous (CC) and lymphocytic colitis (LC) is not well known. The aims of this study were to evaluate the clinical course of microscopic colitis (MC) and to describe the morbidity evolution of the disease. MATERIAL AND METHODS: This study is based on a cohort of 54 patients (35 LC/19 CC), previously included in a randomized trial treated with mesalazine with or without cholestyramine. Patients were followed-up closely during the subsequent 5 years, undergoing clinical, endoscopic and histologic evaluation at least yearly. After this period, they were encouraged to undergo periodical clinical evaluations. RESULTS: In a mean follow-up time of 104.9 ± 14.1 months (range 81-138 months) at the end of the therapy, 12 patients (7 LC and 5 CC) relapsed. Of these patients, 4 reported a mild clinical relapse self-treated with antidiarrheal medication. In total 49 patients are clinically free from diarrhea, to date. At multivariate analysis the only predictive factor of relapse seems to be a slow response to treatment. CONCLUSIONS: Only a minority of patients with MC had diarrhea more than once a week in a long-term follow-up and the symptom pattern was similar between CC and LC patients.


Subject(s)
Colitis, Collagenous/drug therapy , Colitis, Lymphocytic/drug therapy , Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anticholesteremic Agents/therapeutic use , Cholestyramine Resin/therapeutic use , Cohort Studies , Colitis, Collagenous/complications , Colitis, Collagenous/diagnosis , Colitis, Collagenous/pathology , Colitis, Lymphocytic/complications , Colitis, Lymphocytic/diagnosis , Colitis, Lymphocytic/pathology , Diarrhea/etiology , Disease-Free Survival , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Male , Mesalamine/therapeutic use , Multivariate Analysis , Recurrence , Remission Induction , Time Factors , Treatment Outcome
3.
Hist Psychol ; 14(4): 383-404, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22332291

ABSTRACT

The present study embraces the critical traditions of "New History" and of social representations theory articulated with the mainstream historiographical tradition of a bibliometric approach. The historical analysis deals with the early representations of Italian social psychology articulated and disseminated by some of the main Italian scientific-cultural and philosophical journals. We examined seven journals published between 1875 and 1954, and gathered 2,030 texts dealing with the various forms of social and collective psychology. We have applied a grid of content analysis whose data have been transcribed to a numerical file. At the same time, we have created a textual file containing the titles of the contributions as well as the names of the authors and scholars reviewed. The two files have been processed by SPAD-T for a correspondence analysis in which both lexical data and category variables have been considered as active variables. Through the scree-test, two factors that explain 18.90% of the variance have been singled out. Their combination has produced a factorial plan able to highlight three distinct areas differently characterized from journals and years. The results are also discussed with regard to the contextual historical frame.


Subject(s)
Psychology, Social/history , History, 19th Century , History, 20th Century , Italy
4.
J Gastroenterol Hepatol ; 22(6): 809-14, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17565633

ABSTRACT

BACKGROUND: Collagenous colitis (CC) and lymphocytic colitis (LC) are chronic inflammatory diseases of the colon with a benign and sometimes relapsing course. Frequency among patients with chronic diarrhea and normal looking colonoscopy is around 10-15%. To date, treatment of CC and LC is not well defined. Data about these conditions are mostly derived from retrospective studies. The aim of the present study was to evaluate the response to treatment and the clinical course of CC and LC in a large group of patients prospectively diagnosed. METHODS AND RESULTS: A total of 819 patients underwent a colonoscopy because of chronic watery diarrhea and among them we found 41 patients with LC and 23 with CC. These patients were later randomized and assigned to treatment with mesalazine or mesalazine + cholestyramine for 6 months. Fifty-four patients (84.37%) had resolved diarrhea in less than 2 weeks. After 6 months a colonoscopy with biopsies was repeated. Clinical and histological remission was achieved in 85.36% of patients with LC and in 91.3% with CC, with a better result in patients with CC treated with mesalazine + cholestyramine. During a mean period of 44.9 months, 13% of patients relapsed; four with LC and three with CC. They were retreated for another 6 months. At the end of this period one patient with CC was still symptomatic and persistence of CC was confirmed at histology. CONCLUSIONS: Treatment with mesalazine seems to be an effective therapeutic option for LC to date, while mesalazine + cholestyramine seems to be more useful in the treatment of CC.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anticholesteremic Agents/therapeutic use , Cholestyramine Resin/therapeutic use , Colitis, Microscopic/drug therapy , Mesalamine/therapeutic use , Adult , Aged , Biopsy , Chi-Square Distribution , Cholestyramine Resin/administration & dosage , Colonoscopy , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Recurrence , Treatment Outcome
5.
Am J Gastroenterol ; 100(3): 537-42, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15743348

ABSTRACT

BACKGROUND: Dilation of intercellular spaces (DIS) of human esophageal epithelium, evident at transmission electron microscopy (TEM), is an early marker of damage caused by gastroesophageal reflux, but its reversibility after therapy has not been investigated. AIM: To evaluate whether omeprazole can induce the healing of DIS. METHODS: Thirty-eight symptomatic patients, 22 with nonerosive reflux disease (NERD) and 16 with erosive esophagitis (EE), classified on the basis of 24-h pH monitoring, were enrolled. During upper gastrointestinal endoscopy, six biopsies from apparently normal mucosa were taken within the lower 5 cm of the esophagus for histological and TEM analysis. One hundred computer measurements were taken on TEM photomicrographs of the specimens in each patient. After 3 months of omeprazole 40 mg/die a further endoscopy with biopsies was performed. In patients with persistent heartburn and/or incomplete ultrastructural recovery of esophageal epithelium, a new endoscopy was performed after 3 more months of treatment. RESULTS: After 3 months of therapy, 35 patients (92.1%) showed a complete recovery of DIS and resolution of heartburn. Three patients required 3 more months of therapy because of an incomplete recovery of the epithelium correlated with sporadic heartburn. Healing of the mucosa was achieved in two patients, whereas one had an incomplete recovery of DIS with persistent heartburn. CONCLUSIONS: Three and six months of omeprazole therapy led to a complete recovery of DIS in 92.1% and 97.4% of cases, respectively. No significant differences of DIS between NERD and EE were noted. Complete recovery of DIS was accompanied by regression of heartburn in all cases.


Subject(s)
Gastroesophageal Reflux/drug therapy , Gastroesophageal Reflux/pathology , Omeprazole/therapeutic use , Adult , Biopsy , Epithelial Cells/ultrastructure , Esophagitis/pathology , Female , Gastroesophageal Reflux/physiopathology , Heartburn/physiopathology , Humans , Male , Middle Aged , Mucous Membrane/ultrastructure
6.
World J Gastroenterol ; 11(48): 7657-60, 2005 Dec 28.
Article in English | MEDLINE | ID: mdl-16437694

ABSTRACT

AIM: To define the prevalence of gastroesophageal reflux disease (GERD) in mild persistent asthma and to value the effect of pantoprazole therapy on asthmatic symptoms. METHODS: Seven of thirty-four asthmatic patients without GERD served as the non-GERD control group. Twenty-seven of thirty-four asthmatic patients had GERD (7/27 also had erosive esophagitis, sixteen of them presented GERD symptoms. An upper gastrointestinal endoscopy was performed in all the subjects to obtain five biopsy specimens from the lower 5 cm of the esophagus. Patients were considered to have GERD when they had a dilation of intercellular space (DIS) >0.74 mum at transmission electron microscopy. Patients with GERD were treated with pantoprazole, 80 mg/day. Forced expiratory volume in one second (FEV1) was performed at entry and after 6 mo of treatment. Asthmatic symptoms were recorded. The required frequency of inhaling rapid acting beta2-agonists was self-recorded in the patients' diaries. RESULTS: Seven symptomatic patients presented erosive esophagitis. Among the 18 asymptomatic patients, 11 presented DIS, while all symptomatic patients showed ultrastructural esophageal damage. Seven asymptomatic patients did not present DIS. At entry the mean of FEV(1) was 1.91 L in symptomatic GERD patients and 1.88 L in asymptomatic GERD patients. After the treatment, 25 patients had a complete recovery of DIS and reflux symptoms. Twenty-three patients presented a regression of asthmatic symptoms with normalization of FEV(1). Four patients reported a significant improvement of symptoms and their FEV(1) was over 80%. CONCLUSION: GERD is a highly prevalent condition in asthma patients. Treatment with pantoprazole (80 mg/day) determines their improvement and complete regression.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Asthma/etiology , Benzimidazoles/therapeutic use , Gastroesophageal Reflux/drug therapy , Omeprazole/analogs & derivatives , Sulfoxides/therapeutic use , 2-Pyridinylmethylsulfinylbenzimidazoles , Adult , Asthma/physiopathology , Female , Forced Expiratory Volume , Gastroesophageal Reflux/complications , Humans , Male , Middle Aged , Omeprazole/therapeutic use , Pantoprazole
SELECTION OF CITATIONS
SEARCH DETAIL
...